3results about How to "Reduce inflammatory factors" patented technology

This invention belongs to the field of traditional Chinese medicine preparations, and relates to the preparation method and application of a compound preparation of Yao Yu effervescent tablets with anti-rheumatoid arthritis effect. The compound preparation comprises the following traditional Chinese medicine components: 4 parts by weight of Dioscorea cirrhosa, 3 parts by weight of Tinleaf Vine, 2 parts by weight of Camphor Tree, 2 parts by weight of Rhus chinensis, 3 parts by weight of Rhododendron molle, 1 part by weight of Ephedra sinica, 2 parts by weight of Semi-Acer palmatum, 2 parts by weight of Gynostemma pentaphyllum, and 1 part by weight of Cinnamomum cassia. The preparation steps include: placing Dioscorea cirrhosa, Tinleaf Vine, Camphor Tree, Rhus chinensis, Rhododendron molle, Gynostemma pentaphyllum, Semi-Acer palmatum, Gynostemma pentaphyllum, and Cinnamomum cassia in 6000 parts by weight of 70% ethanol. Extract for 2 hours, repeat three times, filter, and combine the filtrates; concentrate, freeze-dry, pulverize, and pass through an 80-mesh sieve for later use; mix 27.5% freeze-dried powder with 26.45% citric acid, 34.11% sodium bicarbonate, 5.61% PEG6000, and 6.33% lactose evenly, pass through an 80-mesh sieve, and prepare a soft mass using anhydrous ethanol as a wetting agent; pass the soft mass through a 20-mesh sieve and dry at 37℃ for 30 minutes to obtain compound preparation granules; granulate through a 20-mesh sieve for granulation, add lubricant PEG6000 and mix evenly; compress into tablets to obtain compound preparation effervescent tablets. This invention, through pharmacological experiments, confirms that the Yaoyu effervescent tablet compound preparation has a good anti-rheumatoid arthritis effect: it can reduce local inflammatory mediators and serum IL-1β, IL-6, TNF-α, and PEG2 levels, downregulate MDA and increase SOD to improve oxidative stress, inhibit the expression of MMP3, COX-2, and P38 proteins in the synovial membrane, and reduce pathological tissue damage. The medium and high dose groups showed the best effect, and it has a good therapeutic and protective effect on the ankle joint of AA rats, with good clinical application value.

This invention relates to the field of biomedical technology and provides a method for preparing uracil-modified gold nanoconjugated materials and their applications. The method includes the following steps: in the presence of a reducing agent, a uracil ligand solution is slowly added to a gold precursor solution for a controlled reduction reaction to form gold nanoconjugated materials with an average particle size ≤2 nm; a thiolated uracil derivative is added to the dispersion of the obtained gold nanoconjugated materials, and the pH of the reaction system is adjusted to alkaline, so that the thiolated uracil derivative is bound to the surface of the gold nanoconjugated materials through Au-S bonds, thereby obtaining uracil-modified gold nanoconjugated materials. This material possesses ultra-small size, pH-responsive surface, and selective uptake characteristics by pathogens, enabling it to efficiently penetrate periodontal biofilms and achieve efficient clearance and virulence blocking against periodontal pathogens by interfering with bacterial proton kinetic potential and inhibiting the secretion of virulence factors.

The application discloses application of anti-IGFBP7 antibodies in treating skin diseases, belongs to the technical field of psoriasis treatment, and discloses application of anti-IGFBP7 antibodies in preparation of a medicament for treating psoriasis, wherein the medicament is used for reducing and treating psoriasis-like inflammation by inhibiting expression of IGFBP7 in blood vessels of skin of a psoriasis patient. After the anti-IGFBP7 antibodies are used, psoriasis inflammation is reduced, meanwhile, epidermal thickness of a psoriasis patient is reduced, erythema formation is inhibited, and the generation of scales is reduced. In protecting vascular barrier function and treating psoriasis, the anti-IGFBP7 antibodies have a good medicinal prospect.